Total Payments
$10,251
2024 Payments
$91.69
Companies
22
Transactions
62
Medicare Patients
1,506
Medicare Billing
$329,777
Payment Breakdown by Category
Consulting$7,290 (71.1%)
Travel$1,644 (16.0%)
Food & Beverage$956.75 (9.3%)
Other$360.00 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,290 | 5 | 71.1% |
| Travel and Lodging | $1,644 | 4 | 16.0% |
| Food and Beverage | $956.75 | 52 | 9.3% |
| Honoraria | $360.00 | 1 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $7,379 | 9 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $1,260 | 1 | $0 (2021) |
| Daiichi Sankyo Inc. | $360.00 | 1 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $350.00 | 1 | $0 (2021) |
| Genentech USA, Inc. | $276.59 | 15 | $0 (2020) |
| Amgen Inc. | $147.85 | 7 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $93.85 | 7 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $44.31 | 3 | $0 (2019) |
| Celgene Corporation | $39.86 | 2 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $37.22 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $91.69 | 4 | Tempus AI, Inc ($33.47) |
| 2023 | $5,423 | 11 | AstraZeneca Pharmaceuticals LP ($5,029) |
| 2021 | $1,610 | 2 | JAZZ PHARMACEUTICALS INC. ($1,260) |
| 2020 | $53.32 | 2 | Amgen Inc. ($30.84) |
| 2019 | $282.13 | 17 | Genentech USA, Inc. ($70.22) |
| 2018 | $2,593 | 15 | AstraZeneca Pharmaceuticals LP ($2,350) |
| 2017 | $197.31 | 11 | Genentech USA, Inc. ($123.56) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $18.28 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: HEMATOLOGY | ||||||
| 01/31/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $33.47 | General |
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $15.25 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | Cash or cash equivalent | $6.53 | General |
| Category: Oncology | ||||||
| 12/04/2023 | Daiichi Sankyo Inc. | — | Honoraria | Cash or cash equivalent | $360.00 | General |
| 11/26/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,497.50 | General |
| Category: Oncology | ||||||
| 11/26/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $832.50 | General |
| Category: Oncology | ||||||
| 11/03/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | Cash or cash equivalent | $708.76 | General |
| Category: Oncology | ||||||
| 11/03/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | Cash or cash equivalent | $708.76 | General |
| Category: Oncology | ||||||
| 11/03/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Travel and Lodging | Cash or cash equivalent | $211.06 | General |
| Category: Oncology | ||||||
| 11/03/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | Cash or cash equivalent | $48.64 | General |
| Category: Oncology | ||||||
| 09/18/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Oncology | ||||||
| 04/04/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2021 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Consulting Fee | Cash or cash equivalent | $1,260.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 01/27/2021 | Janssen Scientific Affairs, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| Category: Oncology | ||||||
| 02/12/2020 | Genentech USA, Inc. | Avastin (Biological) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: BioOncology | ||||||
| 01/29/2020 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $30.84 | General |
| 12/04/2019 | Amgen Inc. | KANJINTI (Biological), MVASI, Neulasta | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Oncology | ||||||
| 11/06/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2019 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ, ROZLYTREK | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: BioOncology | ||||||
| 10/09/2019 | Celgene Corporation | Inrebic (Drug) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Myelofibrosis | ||||||
| 08/21/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.16 | General |
| Category: Oncology | ||||||
| 08/14/2019 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $16.62 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 337 | 748 | $172,085 | $61,262 |
| 2022 | 7 | 389 | 689 | $168,867 | $61,266 |
| 2021 | 7 | 202 | 346 | $81,148 | $28,045 |
| 2020 | 21 | 578 | 1,843 | $773,943 | $179,205 |
Total Patients
1,506
Total Services
3,626
Medicare Billing
$329,777
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 241 | $52,056 | $16,880 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 51 | 129 | $37,797 | $12,866 | 34.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 70 | $20,510 | $9,056 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 81 | $17,496 | $7,358 | 42.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 51 | 110 | $17,160 | $5,157 | 30.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 25 | 25 | $10,150 | $3,354 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 48 | $7,488 | $3,072 | 41.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,902 | $2,640 | 38.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 12 | $1,476 | $540.21 | 36.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 11 | 15 | $1,050 | $339.69 | 32.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 195 | $42,120 | $13,786 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 55 | 120 | $35,160 | $12,848 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 54 | $15,822 | $7,143 | 45.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $15,428 | $5,992 | 38.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 27 | 59 | $12,744 | $5,622 | 44.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 40 | 40 | $16,240 | $5,283 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 56 | 104 | $16,224 | $4,969 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 38 | $5,928 | $2,326 | 39.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,382 | $1,592 | 36.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 16 | $2,432 | $854.34 | 35.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 11 | $2,387 | $849.71 | 35.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 52 | 127 | $27,432 | $9,239 | 33.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 29 | 49 | $14,357 | $5,185 | 36.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 75 | $11,700 | $3,805 | 32.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 26 | 26 | $10,556 | $3,584 | 33.9% |
About Dr. Anna Roshal, MD
Dr. Anna Roshal, MD is a Hematology & Oncology healthcare provider based in Saint Peters, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124081799.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anna Roshal, MD has received a total of $10,251 in payments from pharmaceutical and medical device companies, with $91.69 received in 2024. These payments were reported across 62 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($7,290).
As a Medicare-enrolled provider, Roshal has provided services to 1,506 Medicare beneficiaries, totaling 3,626 services with total Medicare billing of $329,777. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Saint Peters, MO
- Active Since 04/06/2006
- Last Updated 03/05/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1124081799
Products in Payments
- TAGRISSO (Drug) $3,472
- FASLODEX (Drug) $2,350
- IMFINZI (Biological) $1,557
- ZEPZELCA (Drug) $1,260
- CARVYKTI (Drug) $350.00
- Avastin (Biological) $177.11
- Alecensa (Biological) $70.22
- OPDIVO (Biological) $48.66
- Kyprolis (Biological) $46.84
- Neulasta (Biological) $46.41
- KEYTRUDA (Biological) $44.31
- Erleada (Drug) $37.22
- Bavencio (Biological) $32.51
- TECENTRIQ (Biological) $29.26
- IMBRUVICA (Drug) $27.28
- MONOFERRIC (Drug) $24.65
- KANJINTI (Biological) $23.76
- Braftovi (Drug) $22.64
- Xospata (Drug) $20.36
- Revlimid (Drug) $20.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.